We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
Medtronic (MDT - Free Report) ended the recent trading session at $77.32, demonstrating a +1.54% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily loss of 0.07%. At the same time, the Dow added 0.32%, and the tech-heavy Nasdaq lost 0.51%.
The stock of medical device company has fallen by 11.65% in the past month, lagging the Medical sector's loss of 2.17% and the S&P 500's gain of 5.58%.
Analysts and investors alike will be keeping a close eye on the performance of Medtronic in its upcoming earnings disclosure. The company's earnings report is set to go public on June 3, 2026. It is anticipated that the company will report an EPS of $1.58, marking a 2.47% fall compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $9.66 billion, indicating a 8.22% growth compared to the corresponding quarter of the prior year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $5.57 per share and a revenue of $36.15 billion, indicating changes of +1.46% and +7.79%, respectively, from the former year.
Any recent changes to analyst estimates for Medtronic should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Medtronic is currently sporting a Zacks Rank of #4 (Sell).
Looking at its valuation, Medtronic is holding a Forward P/E ratio of 12.51. Its industry sports an average Forward P/E of 17.15, so one might conclude that Medtronic is trading at a discount comparatively.
We can also see that MDT currently has a PEG ratio of 1.81. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products industry had an average PEG ratio of 1.45 as trading concluded yesterday.
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 156, finds itself in the bottom 37% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Medtronic (MDT) Advances While Market Declines: Some Information for Investors
Medtronic (MDT - Free Report) ended the recent trading session at $77.32, demonstrating a +1.54% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily loss of 0.07%. At the same time, the Dow added 0.32%, and the tech-heavy Nasdaq lost 0.51%.
The stock of medical device company has fallen by 11.65% in the past month, lagging the Medical sector's loss of 2.17% and the S&P 500's gain of 5.58%.
Analysts and investors alike will be keeping a close eye on the performance of Medtronic in its upcoming earnings disclosure. The company's earnings report is set to go public on June 3, 2026. It is anticipated that the company will report an EPS of $1.58, marking a 2.47% fall compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $9.66 billion, indicating a 8.22% growth compared to the corresponding quarter of the prior year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $5.57 per share and a revenue of $36.15 billion, indicating changes of +1.46% and +7.79%, respectively, from the former year.
Any recent changes to analyst estimates for Medtronic should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Medtronic is currently sporting a Zacks Rank of #4 (Sell).
Looking at its valuation, Medtronic is holding a Forward P/E ratio of 12.51. Its industry sports an average Forward P/E of 17.15, so one might conclude that Medtronic is trading at a discount comparatively.
We can also see that MDT currently has a PEG ratio of 1.81. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products industry had an average PEG ratio of 1.45 as trading concluded yesterday.
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 156, finds itself in the bottom 37% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.